Skip to Content

Posts tagged with "Drug Development"

  • Academia (vs. Industry)

    Magic Open Source Savings Await

    I’ve never known quite what to make of the “open source pharma” idea. I know that there are a lot of people working on things in this area, and that there’s a lot of interest. But as someone who does drug discovery for a living, I can’t quite see how it can work. And I’m… Read More
  • Drug Development

    Picturing A Drug Effort’s Progress

    Lead optimization – that’s what people think about when they think about medicinal chemistry, assuming that they ever do. “Lead op” is where compounds get whipped into drug candidates, through iterative rounds of synthesis and testing, and if that sounds straightforward, then you haven’t had a chance to try it: Given t… Read More
  • Clinical Trials

    The Wildly Unlikely Return of TGN1412

    You may be familiar with the bizarre story of TGN1412, an immunotherapy developed (briefly) by a small German company called TeGenero in 2006. This led to the infamous Phase I incident in England where a set of six volunteers were dosed at fifteen-minute intervals, but right after the last one got the injection, the first… Read More
  • Cancer

    ABT-199 Nears Its Finish Line

    A couple of years back, AbbVie ran into an unusual problem in the clinic. Their Bcl ligand, ABT-199, was working a bit too well, and killing off so many leukemia cells that the resulting cellular debris was causing kidney trouble in some patients. The company immediately started working on clinical protocols to get things restarted… Read More
  • Drug Development

    Modeling the Rats, Who Model the Humans

    When you get down to it, one of the biggest problems in drug discovery is that there is (in most cases) no alternative but doing things the hard way. If you want to find out if your drug is going to work for a given disease, there’s no other way to be sure than to… Read More
  • Business and Markets

    The Wild Ride of AQX-1125

    If you’re wondering why people invest in speculative little biopharma stocks, look no further than Aquinox Pharmaceuticals. But if you’re looking for why people shouldn’t invest in speculative little biopharma stocks, you might look no further, anyway. The company’s lead compound, AQX-1125, is supposed to be an activator of… Read More
  • Alzheimer's Disease

    On the FDA, Drug Approvals, and Not Knowing Enough

    It doesn’t seem to have generated many headlines, but the FDA recently released a report (PDF) on the pace of drug development. Titled “Targeted Drug Development: Why Are Many Diseases Lagging Behind”, it seems to be motivated, at least in part, by a desire to answer “Not Because of Us!” The agency goes into some deta… Read More
  • Chemical Biology

    The Problems That the Synthesis Machine Won’t Solve

    Martin Burke, a chemist at the University of Illinois, made a big splash some months back with his “synthesis machine”. And I have to confess, I probably helped some of the water fly through the air. I’d heard him talk about this technology, and I was very impressed, and I found the subsequent paper impressive… Read More
  • Drug Development

    A 3D Printed Drug?

    Several readers have sent along news of what’s billed as the “world’s first 3D-printed drug”. That got my attention, because there have been some rather wild predictions about the effects of that technology on drug discovery, some of them weird in the extreme. On checking this out, though, I found that it would be more accu… Read More
  • Drug Assays

    The End of Compound Property Optimization Is At Hand

    Here’s another Big Retrospective Review of drug pipeline attrition. This sort of effort goes back to the now-famous Rule-of-Five work, and readers will recall the Pfizer roundup of a few years back, followed by an AstraZeneca one (which didn’t always recapitulate the Pfizer pfindings, either). This latest is a joint effort to look at th… Read More
...91011...